A carregar...
Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
Objective: Breast cancer remains to be the globally leading female cancer. About 15% to 20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive tumors – a more aggressive breast cancer subtype with shortened survival. In the light of new and updated trial data on trastuzu...
Na minha lista:
| Publicado no: | Expert Rev Clin Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6816496/ https://ncbi.nlm.nih.gov/pubmed/31287333 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2019.1637252 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|